

Highlights of This Issue 3521

SPECIAL FEATURES

CCR Translations

- 3523 | **PIKing the Right Patient**
Alexa B. Turke and Jeffrey A. Engelman
See article p. 3670

Molecular Pathways

- 3526 | **Advances in Targeting Src in the Treatment of Breast Cancer and Other Solid Malignancies**
Erica L. Mayer and Ian E. Krop
- 3533 | **Prostate Stem Cell Antigen: A Jekyll and Hyde Molecule?**
Norihsa Saeki, Jian Gu, Teruhiko Yoshida, and Xifeng Wu

- 3571 | **L1 Cell Adhesion Molecule Is a Novel Therapeutic Target in Intrahepatic Cholangiocarcinoma**
Jeong-Ki Min, Jin-Man Kim, Shengjin Li, Jung Whoi Lee, Hyunho Yoon, Chun Jeih Ryu, Soung Hoo Jeon, Jae-Hyek Lee, Jin Young Kim, Hee Kwan Yoon, Young Kwan Lee, Bong-Hui Kim, Yeon Sung Son, Hong Seo Choi, Nam-Kyu Lim, Dae-Ghon Kim, and Hyo Jeong Hong

- 3581 | **Functional Mapping of Receptor Tyrosine Kinases in Myxoid Liposarcoma**
Tiziana Negri, Emanuela Viridis, Silvia Brich, Fabio Bozzi, Elena Tamborini, Eva Tarantino, Genny Jocolle, Giuliana Cassinelli, Federica Grosso, Roberta Sanfilippo, Patrizia Casalini, Angela Greco, Marco A. Pierotti, and Silvana Pilotti

HUMAN CANCER BIOLOGY

- 3539 | **Identification of Differentially Methylated Genes in Normal Prostate Tissues from African American and Caucasian Men**
Bernard Kwabi-Addo, Songping Wang, Woonbok Chung, Jaroslav Jelinek, Steven R. Patierno, Bi-Dar Wang, Ramez Andrawis, Norman H. Lee, Victor Apprey, Jean-Pierre Issa, and Michael Ittmann
- 3548 | **Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers**
Neil R. Smith, Dawn Baker, Neil H. James, Kirsty Ratcliffe, Martin Jenkins, Susan E. Ashton, Graham Sproat, Ruth Swann, Neil Gray, Anderson Ryan, Juliane M. Jürgensmeier, and Chris Womack
- 3562 | **Cancer-Testis Antigens and Immunosurveillance in Human Cutaneous Squamous Cell and Basal Cell Carcinomas**
Anne Walter, Marjam J. Barysch, Silvia Behnke, Piotr Dziunycz, Bruno Schmid, Erika Ritter, Sacha Gnjatic, Glen Kristiansen, Holger Moch, Alexander Knuth, Reinhard Dummer, and Maries van den Broek

CANCER THERAPY: PRECLINICAL

- 3594 | **Successful Eradication of Established Peritoneal Ovarian Tumors in SCID-Beige Mice following Adoptive Transfer of T Cells Genetically Targeted to the MUC16 Antigen**
Alena A. Chekmasova, Thapi D. Rao, Yan Nikhamin, Kay J. Park, Douglas A. Levine, David R. Spriggs, and Renier J. Brentjens
- 3607 | **A Novel Nanoparticulate Formulation of Arsenic Trioxide with Enhanced Therapeutic Efficacy in a Murine Model of Breast Cancer**
Richard W. Ahn, Feng Chen, Haimei Chen, Stephan T. Stern, Jeffrey D. Clogston, Anil K. Patri, Meera R. Raja, Elden P. Swindell, Vamsi Parimi, Vincent L. Cryns, and Thomas V. O'Halloran
- 3618 | **Angiopoietin-2 Interferes with Anti-VEGFR2-Induced Vessel Normalization and Survival Benefit in Mice Bearing Gliomas**
Sung-Suk Chae, Walid S. Kamoun, Christian T. Farrar, Nathaniel D. Kirkpatrick, Elisabeth Niemeyer, Annemarie M.A. de Graaf, A. Gregory Sorensen, Lance L. Munn, Rakesh K. Jain, and Dai Fukumura

- 3628 **The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma**
Daniel C. Cho, Matthew B. Cohen, David J. Panka, Michael Collins, Musie Ghebremichael, Michael B. Atkins, Sabina Signoretti, and James W. Mier
- 3639 **Augmentation of Radiation Response by Motesanib, a Multikinase Inhibitor that Targets Vascular Endothelial Growth Factor Receptors**
Tim J. Kruser, Deric L. Wheeler, Eric A. Armstrong, Mari Iida, Kevin R. Kozak, Albert J. van der Kogel, Johan Bussink, Angela Coxon, Anthony Polverino, and Paul M. Harari
- 3648 **Pralatrexate Is Synergistic with the Proteasome Inhibitor Bortezomib in *In vitro* and *In vivo* Models of T-Cell Lymphoid Malignancies**
Enrica Marchi, Luca Paoluzzi, Luigi Scotto, Venkatraman E. Seshan, Jasmine M. Zain, Pier Luigi Zinzani, and Owen A. O'Connor
- 3659 **Angiogenin Regulation by Estradiol in Breast Tissue: Tamoxifen Inhibits Angiogenin Nuclear Translocation and Antiangiogenin Therapy Reduces Breast Cancer Growth *In vivo***
Ulrika W. Nilsson, Annelie Abrahamsson, and Charlotta Dabrosin
- 3670 **Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3' Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models**
Carol O'Brien, Jeffrey J. Wallin, Deepak Sampath, Debraj GuhaThakurta, Heidi Savage, Elizabeth A. Punnoose, Jane Guan, Leanne Berry, Wei Wei Prior, Lukas C. Amler, Marcia Belvin, Lori S. Friedman, and Mark R. Lackner
See commentary p. 3523
- 3684 **Development of an Orthotopic Model of Invasive Pancreatic Cancer in an Immunocompetent Murine Host**
William W. Tseng, Daniel Winer, Justin A. Kenkel, Okmi Choi, Alan H. Shain, Jonathan R. Pollack, Randy French, Andrew M. Lowy, and Edgar G. Engleman
- 3696 **Potent Antitumor Activity in Experimental Hepatocellular Carcinoma by Adenovirus-Mediated Coexpression of TRAIL and shRNA against COX-2**
Qing Chen, Wenjia Lou, Junjie Shen, Leina Ma, Zhi Yang, Li Liu, Jingjing Luo, and Cheng Qian

IMAGING, DIAGNOSIS, PROGNOSIS

- 3706 **Prognostic Significance of Telomerase Polymorphism in Non-Small Cell Lung Cancer**
Raquel Catarino, António Araújo, Ana Coelho, Mónica Gomes, Augusto Nogueira, Carlos Lopes, and Rui M. Medeiros
- 3713 **Mature MicroRNA Sequence Polymorphism in MIR196A2 Is Associated with Risk and Prognosis of Head and Neck Cancer**
Brock C. Christensen, Michele Avissar-Whiting, Lauren G. Ouellet, Rondi A. Butler, Heather H. Nelson, Michael D. McClean, Carmen J. Marsit, and Karl T. Kelsey
- 3721 **Dynamic Single-Cell Network Profiles in Acute Myelogenous Leukemia Are Associated with Patient Response to Standard Induction Therapy**
Steven M. Kornblau, Mark D. Minden, David B. Rosen, Santosh Putta, Aileen Cohen, Todd Covey, David C. Spellmeyer, Wendy J. Fantl, Urte Gayko, and Alessandra Cesano
- 3734 **High Levels of Nucleolar Expression of Nucleolin Are Associated with Better Prognosis in Patients with Stage II Pancreatic Ductal Adenocarcinoma**
Lan Peng, John Liang, Hua Wang, Xianzhou Song, Asif Rashid, Henry F. Gomez, Lynda J. Corley, James L. Abbruzzese, Jason B. Fleming, Douglas B. Evans, and Huamin Wang
- 3743 **Nrf2 and Keap1 Abnormalities in Non-Small Cell Lung Carcinoma and Association with Clinicopathologic Features**
Luisa M. Solis, Carmen Behrens, Wenli Dong, Milind Suraokar, Natalie C. Ozburn, Cesar A. Moran, Alejandro H. Corvalan, Shyam Biswal, Stephen G. Swisher, B. Nebiyu Bekele, John D. Minna, David J. Stewart, and Ignacio I. Wistuba
- 3754 **Ten Common Genetic Variants Associated with Colorectal Cancer Risk Are Not Associated with Survival after Diagnosis**
Albert Tenesa, Evropi Theodoratou, Farhat V.N. Din, Susan M. Farrington, Roseanne Cetnarskyj, Rebecca A. Barnetson, Mary E. Porteous, Harry Campbell, and Malcolm G. Dunlop

3760 **Development of Autoantibody Signatures as Novel Diagnostic Biomarkers of Non–Small Cell Lung Cancer**
Lingling Wu, Wenjun Chang, Jinfeng Zhao, Yongwei Yu, Xiaojie Tan, Tong Su, Lijun Zhao, Shengdong Huang, Shiyuan Liu, and Guangwen Cao

3769 **Intercohort Gene Expression Co-Analysis Reveals Chemokine Receptors as Prognostic Indicators in Ewing’s Sarcoma**
Idriss M. Bennani-Baiti, Aaron Cooper, Elizabeth R. Lawlor, Maximilian Kauer, Jozef Ban, Dave N.T. Aryee, and Heinrich Kovar

3779 **A Functional Variant of Tandem Repeats in Human Telomerase Gene Was Associated with Survival of Patients with Early Stages of Non–Small Cell Lung Cancer**
Luo Wang, Li-E Wang, Li Mao, Margaret R. Spitz, and Qingyi Wei

3795 **Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin**
Ulka N. Vaishampayan, Angelika M. Burger, Edward A. Sausville, Lance K. Heilbrun, Jing Li, M. Naomi Horiba, Merrill J. Egorin, Percy Ivy, Simon Pacey, and Patricia M. LoRusso

LETTER TO THE EDITOR

3805 **Comparison of Choi and Hans’ Algorithms by Immunohistochemistry and Quantitative Reverse Transcriptase-PCR – Letter**
Erica Ballabio, Jianxiang Chi, Giovanna Roncador, Alison H. Banham, Christian S.R. Hatton, and Charles H. Lawrie

CORRECTIONS

3807 **Correction: Performing Phase I Clinical Trials of Anticancer Agents: Perspectives from within the European Union and Japan**


3807 **Correction: Establishment and Characterization of a Panel of Human Uveal Melanoma Xenografts Derived from Primary and/or Metastatic Tumors**

CANCER THERAPY: CLINICAL

3786 **A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Two Schedules of Vorinostat in Combination with 5-Fluorouracil and Leucovorin in Patients with Refractory Solid Tumors**
Marwan G. Fakih, Gerald Fetterly, Merrill J. Egorin, Josephia R. Muindi, Igor Espinoza-Delgado, James A. Zwiebel, Alan Litwin, Julianne L. Holleran, Kangsheng Wang, and Robert B. Diasio

ABOUT THE COVER

Transmission electron micrograph shows 100 nm lipid vesicles that contain a highly concentrated complex of arsenic trioxide (> 270 mmol/L). This nanoparticulate formulation (termed “nanobin”) markedly improves the pharmacokinetics of the cytotoxic agent, resulting in enhanced antitumor efficacy in a murine model of breast cancer. Nanobin encapsulation of arsenic trioxide may increase its therapeutic utility in breast cancer and potentially other solid tumors. For further details, please see the article by Ahn and colleagues on page 3607 of this issue.



Clinical Cancer Research

16 (14)

Clin Cancer Res 2010;16:3521-3807.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/16/14>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/16/14>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.